Please assess the completion status of the following clinical trial:

Trial Title: Abiraterone Acetate in Castration-Resistant Prostate Cancer Previously Treated With Docetaxel-Based Chemotherapy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Metastatic Castration-Resistant Prostate Cancer Progression after one or two prior cytotoxic chemotherapies~* At least one chemotherapy must have contained docetaxel~* Eastern Cooperative Oncology Group (ECOG) Performance Status \<= 2~* Medical or surgical castration with testosterone \< 50 ng/dL~* Adequate bone marrow, hepatic and renal function~* Potassium \>= 3.5 mmol/L~* Able to swallow the study drug whole as a tablet~* Informed Consent~Exclusion Criteria:~* More than two prior cytotoxic chemotherapy regimens~* Prior Ketoconazole for prostate cancer~* Prior abiraterone acetate or other CYP17 inhibitor or investigational agents targeting the androgen receptor for prostate cancer~* Uncontrolled hypertension~* Active or symptomatic viral hepatitis or chronic liver disease~* History of pituitary or adrenal dysfunction~* Clinically significant heart disease~* Other malignancy~* Known brain metastasis~* GI disorder affecting absorption~* Not willing to use contraception

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Abiraterone acetate plus prednisone/prednisolone (Type: EXPERIMENTAL): None
- Placebo plus prednisone/prednisolone (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).